OpenEvidence Valued at $15B as AI-for-Doctors Race Heats Up

OpenEvidence, an AI search engine built specifically for physicians, has closed a $250 million funding round led by hospital systems and Andreessen Horowitz, pushing its valuation to $15 billion. That follows a January round that valued the Miami-based startup at $12 billion — meaning it has added $3 billion in valuation in under a year and raised over $1 billion in total during that stretch. Investors include a who's-who of venture capital: Thrive Capital, DST, GV, Kleiner Perkins, Sequoia Capital, and Nvidia.

The company's growth numbers are striking. OpenEvidence claims more than two-thirds of U.S. doctors use its product for diagnostic and treatment guidance, and it has described itself as the fastest-growing physician application in history. Founded in 2022, it has built deep integrations with Google and Microsoft's AI tools and announced a new partnership with Anthropic this week, giving it relationships across virtually every major AI platform.

Despite that momentum, OpenEvidence may not stay independent for long. The company is said to be open to acquisition conversations, partly because its ownership of computing infrastructure could become a strategic asset if anti-AI sentiment slows data center expansion and GPU access tightens. For a buyer, the appeal is obvious: a ready-made user base of doctors, proven regulatory and compliance experience with sensitive medical data, and a dominant foothold in healthcare — a market OpenAI, Anthropic, and other AI giants are now aggressively targeting with their own products rather than just powering others'.

The acquisition chatter fits into a broader AI M&A wave. Nvidia recently agreed to acquire HuggingFace for nearly $13 billion, and Stripe struck a deal to buy OpenRouter for roughly $8 billion, as competition for AI talent and distribution intensifies across the industry.